Fampridine-SR and Optic Neuritis Recovery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-22

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop MS. These ON events present with a decline in vision over several days with painful eye movements. The purpose of this study is to collect pilot data on the effect of Fampridine-SR on the recovery of visual function after demyelinating optic neuritis.Our team evaluated a person with ON who had incomplete recovery which was quite bothersome to her. After a one-month treatment course Fampridine SR,her visual functioning improved. Based on this case, we present a unique opportunity to evaluate the potential benefit of Fampridine-SR as a potential treatment for persons who do not fully recover from acute ON.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?

NCT01667497

Cognitive Fatigue

COMPLETED PHASE2/PHASE3

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530

Multiple Sclerosis

COMPLETED PHASE3

Amiloride Clinical Trial In Optic Neuritis

NCT01802489

Optic Neuritis Multiple Sclerosis

COMPLETED PHASE2

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927

Multiple Sclerosis

COMPLETED PHASE3

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986

Multiple Sclerosis Optic Neuritis

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop MS. ON usually presents with a decline in vision over several days to weeks with painful eye movements.

Fampridine-SR is currently a Health Canada approved medication to treat walking impairment in persons with MS. Some small studies in the past have shown that Fampridine-SR may also have positive effects on visual functioning in those experiencing ON.

This study will aim to assess the effect of taking Fampridine-SR for 8 weeks in 20 MS patients with unresolved optic neuritis on measures of visual functioning, and to determine the best measures to use in a future large scale study. The results of this study will also be used to estimate how many participants we will need in the future large scale study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Optic Neuritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fampridine-SR

Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.

Group Type EXPERIMENTAL

Fampridine SR

Intervention Type DRUG

Fampridine-SR 10 mg twice daily for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fampridine SR

Fampridine-SR 10 mg twice daily for 8 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have an MS diagnosis, any type
* Had an acute optic neuritis without full recovery which occurred ≥ one year ago
* Have a visual acuity in the affected of eye of ≥ 20/40 or

1. Or ≥20 ms difference in VEP between eyes
2. Or ≥ 120 ms VEP in the affected eye
* Have not received corticosteroids in the last thirty (30) days
* Medications that could potentially affect the VEP P100 amplitude or may cause drowsiness/difficulty with visual fixation are allowed if there has been no change in dose within 30 days of study enrollment or anytime during the study. These medications include:

1. Benzodiazepines other than every night at bedtime
2. Opioid and opiates other than every night at bedtime
3. Cannabinoid products other than every night at bedtime
* Have given written informed consent prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care

Exclusion Criteria

* Have another medical condition that could affect the visual outcomes, such as, but not limited to, diabetes retinopathy, glaucoma, cataracts, previous ocular trauma, amblyopia, and optic neuropathy not due to a demyelinating lesion
* Creatinine clearance ≤ 80 mL/min
* Has a history of seizures, with the exception of febrile seizure as an infant
* Taking a medicinal product that is an inhibitor of Organic Cation Transporter 2 (OCT-2)

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No